American researchers have developed an innovative blood test based on circulating tumor DNA, capable of distinguishing patients with metastatic prostate cancer according to their prognosis.
- American researchers have developed AR-ctDETECT, an innovative blood test based on circulating tumor DNA capable of distinguishing patients with metastatic prostate cancer according to their prognosis.
- The trial, involving 770 samples, found that the presence of detectable tumor DNA is linked to reduced survival.
- By targeting specific cancer genes, this test promises more personalized and tailored treatments. It could also predict the effectiveness of certain therapies, revolutionizing patient care.
A team of researchers from the Universities of Minnesota and Duke, in the United States, have developed a revolutionary blood test that could change the management of patients with advanced prostate cancer. Published in the journal Nature Communicationstheir study reveals how this test can differentiate patients with a favorable outlook from those with a poorer prognosis.
A test based on circulating tumor DNA
The blood test, called AR-ctDETECT, is based on the detection of fragments of circulating tumor DNA, that is to say the DNA released by tumors into the blood. It particularly targets patients with metastatic prostate cancer, an advanced and difficult-to-treat form of the disease. In a phase 3 clinical trial involving more than 770 blood samples, AR-ctDETECT identified the presence of tumor DNA in 59% of patients.
The study shows that patients with detectable circulating tumor DNA have significantly reduced overall survival compared to those who tested negative. “These results highlight the potential of the AR-ctDETECT test to provide crucial genetic information and personalize treatments according to patient profiles”explain the researchers in a press release.
Towards more personalized medicine
One of the strengths of the test is its ability to analyze genes specific to prostate cancer and hormone resistance, including those related to the androgen receptor. “By integrating this genomic data into clinical decisions, we will be able to improve treatment strategies and design more tailored clinical trials”according to scientists.
This pioneering study opens up numerous perspectives. The authors plan to study how to integrate results from the AR-ctDETECT test with clinical data to refine predictions about disease progression. They will also assess whether the test can predict the effectiveness of certain treatments, paving the way for optimal, tailored therapy.
